White Paper

Antibody-Drug Conjugates: Bridging Precision and Potency in Oncology

Antibody-drug conjugates (ADCs) are a class of medicines that target and destroy cancer cells with cytotoxic drug payloads covalently attached to monoclonal antibodies (mAbs) via chemical linkers. For an ADC to be successful, the right combination of target-antigen, active linker, cytotoxic payload, drug-to-antibody ratio (DAR) and payload conjugation site need to be considered.

This white paper explores the key features of antibody-drug conjugates and different preclinical solutions for accelerating the development of this specific drug modality. Finally, this white paper includes a case studies which go into further detail of specific assays used in the development of antibody-drug conjugates.

Download this White Paper to Discover:

• Overview of ADCs: Read an overview of how antibody-drug conjugate (ADCs) work and explore the potential of these innovative therapies in precision oncology, including key attributes for drug development.
  
  
• The latest pre-clinical models for ADC development: Learn more about recent technological advances and preclinical models that are driving the next generation of antibody-drug conjugates (ADCs) including PDX and 3D organoids.
  
  
• Preclinical case study: Gain insights from a comprehensive case study which compares the penetration of trastuzumab (Herceptin) and T-DM1 (Kadcyla) in gastric cancer organoid screening platforms.

Download the White Paper Now!